Evidence map›Paper›PMID 32116435›Full record

ArticleEthiopian journal of health sciences2020

Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran.

Seifu Gizaw Feysia, Malihe Hasan-Nejad, Siroos Amini, Gholamreza Hamzelou, Hossein Kazemian, Jalil Kardan-Yamchi, Morteza Karami-Zarandi, Mohammad Mehdi Feizabadi

Open access · diamondAbstract read
In one paragraph

Article in Ethiopian journal of health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Prevalence ofFrontiers in microbiology · 2024
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Seifu Gizaw FeysiaDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Malihe Hasan-NejadDepartment of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Iranian Research Center for HIV/AIDS.
Siroos AminiReferral Tuberculosis Laboratory, Tehran University of Medical Sciences, Tehran, Iran.
Gholamreza HamzelouReferral Tuberculosis Laboratory, Tehran University of Medical Sciences, Tehran, Iran.
Hossein KazemianDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Jalil Kardan-YamchiDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Morteza Karami-ZarandiDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Mehdi FeizabadiDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRIlam University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNontuberculous mycobacterial (NTM) infections have radically increased worldwide due to the increase in HIV infections. The disease activity increases with progressive immunodeficiency.

methodsA total of 216 HIV seropositive patients suspected of having mycobacterial infection were recruited for this study. Clinical samples were collected from each patient and cultured on Lowenstein-Jensen media. Detection and species identification were simultaneously done using Reverse Blot Hybridization Assay System. Also, the minimum inhibitory concentrations (MIC) for each isolate were determined in 7H9 broth media for 10 antibiotics.

resultsIn this study, 4 rapid and 4 slow-growing NTM species were isolated and identified. Mycobacterium fortuitum was the most common NTM species, 3/8 (37.5%), followed by Mycobacterium kansasii, 2/8 (25%). The cases were identified as pulmonary disease, 5/8 (62.5 %), disseminated infection, 2/8 (25%), and skin abscess, 1/8 (12.5%). M. chelonae and Mycobacterium avium were isolated from patients diagnosed with disseminated infection with treatment failure. The skin abscess was caused by infection with M. simiae. The results of the MIC testing were as follows: M. kansasii and M. fortuitum were susceptible to amikacin (AMK); M. avium to clarithromycin (CLA); M. fortuitum 2/3 (67%) to ciprofloxacin (CIP); 1/2 (50%) of M. kansasii isolates to CLA, and M. chelonae to rifampin (RIF), linezolid (LIN), AMK, and CIP at medium and high concentrations.

conclusionAMK showed incredible in vitro activity against M. kansasii and M. fortuitum. Also, M. avium was susceptible to CLA, whereas M. simiae and M. chelonae were resistant to the tested drugs in this study.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibiotics, AntitubercularCiprofloxacinFemaleHIV InfectionsHumansIncidenceIranMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium Infections, NontuberculousNontuberculous MycobacteriaAntibiotics, AntitubercularCiprofloxacinRifampinAbscessMicrodilutionMinimum inhibitory concentrationsNontuberculous mycobacteria

Identifiers

PMID32116435
PMCPMC7036467
OpenAlexW3012315244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.